首页 > 最新文献

Neuro-oncology practice最新文献

英文 中文
Forthcoming Meetings 即将到来的会议
Q2 Medicine Pub Date : 2023-09-15 DOI: 10.1093/nop/npad052
Jennie W Taylor
Journal Article Forthcoming Meetings Get access Jennie W Taylor Jennie W Taylor Search for other works by this author on: Oxford Academic Google Scholar Neuro-Oncology Practice, Volume 10, Issue 5, October 2023, Page 495, https://doi.org/10.1093/nop/npad052 Published: 15 September 2023 Article history Corrected and typeset: 15 September 2023 Published: 15 September 2023
期刊文章即将召开的会议获取访问Jennie W Taylor Jennie W Taylor搜索作者的其他作品:牛津学术谷歌学者神经肿瘤学实践,第10卷,第5期,2023年10月,第495页,https://doi.org/10.1093/nop/npad052出版:2023年9月15日文章历史更正和排版:2023年9月15日出版:2023年9月15日
{"title":"Forthcoming Meetings","authors":"Jennie W Taylor","doi":"10.1093/nop/npad052","DOIUrl":"https://doi.org/10.1093/nop/npad052","url":null,"abstract":"Journal Article Forthcoming Meetings Get access Jennie W Taylor Jennie W Taylor Search for other works by this author on: Oxford Academic Google Scholar Neuro-Oncology Practice, Volume 10, Issue 5, October 2023, Page 495, https://doi.org/10.1093/nop/npad052 Published: 15 September 2023 Article history Corrected and typeset: 15 September 2023 Published: 15 September 2023","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135395584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing an exercise training program in pediatric brain tumour survivors: Does timing postradiotherapy matter? 优化儿童脑肿瘤幸存者的运动训练计划:放疗后时间重要吗?
IF 2.4 Q2 CLINICAL NEUROLOGY Pub Date : 2023-09-09 eCollection Date: 2024-02-01 DOI: 10.1093/nop/npad055
Éloïse Baudou, Jennifer L Ryan, Elizabeth Cox, Lisa Nham, Krista Johnston, Éric Bouffet, Ute Bartels, Brian Timmons, Cynthia de Medeiros, Donald J Mabbott

Background: While exercise training (ET) programs show positive outcomes in cognition, motor function, and physical fitness in pediatric brain tumor (PBT) survivors, little is known about the optimal timing of intervention. The aim of this work was to explore the feasibility and benefits of ET based on its timing after radiotherapy.

Methods: This retrospective analysis (ClinicalTrials.gov, NCT01944761) analyzed data based on the timing of PBT survivors' participation in an ET program relative to their completion of radiotherapy: <2 years (n = 9), 2-5 years (n = 10), and > 5 years (n = 13). We used repeated measures analysis of variance to compare feasibility and efficacy indicators among groups, as well as correlation analysis between ET program timing postradiotherapy and preliminary treatment effects on cognition, motor function and physical fitness outcomes.

Results: Two to five years postradiotherapy was the optimal time period in terms of adherence (88.5%), retention (100%), and satisfaction (more fun, more enjoyable and recommend it more to other children). However, the benefits of ET program on memory recognition (r = -0.379, P = .047) and accuracy (r = -0.430, P = .032) decreased with increased time postradiotherapy. Motor function improved in all groups, with greater improvements in bilateral coordination (P = .043) earlier postradiotherapy, and in running (P = .043) later postradiotherapy. The greatest improvement in pro-rated work rate occurred in the < 2-year group (P = .008).

Conclusion: Participation in an ET program should be offered as part of routine postradiotherapy care in the first 1-2 years and strongly encouraged in the first 5 years.

虽然运动训练(ET)项目在儿童脑肿瘤(PBT)幸存者的认知、运动功能和身体健康方面显示出积极的结果,但对干预的最佳时机知之甚少。本研究的目的是探讨放疗后放疗时机的可行性和益处。这项回顾性分析(ClinicalTrials.gov, NCT01944761)分析了PBT幸存者参与ET计划的时间与放疗完成的时间:5年(n=13)。我们采用重复计量方差分析比较各组间可行性和疗效指标,并分析放疗后ET节目时间与前期治疗效果对认知、运动功能和体质结局的相关性。放疗后2 - 5年是依从性(88.5%)、保持率(100%)和满意度(更有趣、更愉快并更推荐给其他儿童)的最佳时间段。然而,随着放疗后时间的延长,ET方案在记忆识别(r=-0.379, p=0.047)和准确性(r=-0.430, p=0.032)方面的益处有所下降。各组患者运动功能均有改善,放疗后早期双侧协调能力(p=0.043)和放疗后后期跑步能力(p=0.043)均有较大改善。在比例工作率改善最大发生在<2年组(p=0.008)。在最初的1-2年内,应将ET计划作为常规放疗后护理的一部分,并强烈鼓励在最初的5年内进行ET计划。
{"title":"Optimizing an exercise training program in pediatric brain tumour survivors: Does timing postradiotherapy matter?","authors":"Éloïse Baudou, Jennifer L Ryan, Elizabeth Cox, Lisa Nham, Krista Johnston, Éric Bouffet, Ute Bartels, Brian Timmons, Cynthia de Medeiros, Donald J Mabbott","doi":"10.1093/nop/npad055","DOIUrl":"10.1093/nop/npad055","url":null,"abstract":"<p><strong>Background: </strong>While exercise training (ET) programs show positive outcomes in cognition, motor function, and physical fitness in pediatric brain tumor (PBT) survivors, little is known about the optimal timing of intervention. The aim of this work was to explore the feasibility and benefits of ET based on its timing after radiotherapy.</p><p><strong>Methods: </strong>This retrospective analysis (ClinicalTrials.gov, NCT01944761) analyzed data based on the timing of PBT survivors' participation in an ET program relative to their completion of radiotherapy: <2 years (<i>n</i> = 9), 2-5 years (<i>n</i> = 10), and > 5 years (<i>n</i> = 13). We used repeated measures analysis of variance to compare feasibility and efficacy indicators among groups, as well as correlation analysis between ET program timing postradiotherapy and preliminary treatment effects on cognition, motor function and physical fitness outcomes.</p><p><strong>Results: </strong>Two to five years postradiotherapy was the optimal time period in terms of adherence (88.5%), retention (100%), and satisfaction (more fun, more enjoyable and recommend it more to other children). However, the benefits of ET program on memory recognition (<i>r</i> = -0.379, <i>P</i> = .047) and accuracy (<i>r</i> = -0.430, <i>P</i> = .032) decreased with increased time postradiotherapy. Motor function improved in all groups, with greater improvements in bilateral coordination (<i>P</i> = .043) earlier postradiotherapy, and in running (<i>P</i> = .043) later postradiotherapy. The greatest improvement in pro-rated work rate occurred in the < 2-year group (<i>P</i> = .008).</p><p><strong>Conclusion: </strong>Participation in an ET program should be offered as part of routine postradiotherapy care in the first 1-2 years and strongly encouraged in the first 5 years.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10785595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44978280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ventriculoperitoneal shunting with an on-off valve for patients with leptomeningeal metastases and intracranial hypertension. 脑膜轻脑膜转移和颅内高压患者使用开关阀进行脑室-腹膜分流
IF 2.4 Q2 CLINICAL NEUROLOGY Pub Date : 2023-09-02 eCollection Date: 2024-02-01 DOI: 10.1093/nop/npad056
Kristin M Huntoon, Jaime Gasco, Isabella C Glitza Oliva, Sherise D Ferguson, Nazarin K Majd, Ian E McCutcheon

Background: We report our experience with using a ventriculoperitoneal shunt (VPS) with an on-off valve and in-line Ommaya reservoir for the treatment of hydrocephalus or intracranial hypertension in patients with leptomeningeal disease (LMD). Our goal was to determine whether control of intracranial pressure elevation combined with intrathecal (IT) chemotherapy would extend patient survival.

Methods: In this IRB-approved retrospective study, we reviewed 58 cases of adult patients with LMD from solid cancers who received a VPS with a reservoir and an on-off valve at M D Anderson Cancer Center from November 1996 through December 2021. Primary tumors were most often melanoma (n = 19) or breast carcinoma (n = 20). Hydrocephalus was diagnosed by clinical symptoms and findings on magnetic resonance imaging (MRI), and LMD by MRI or cerebrospinal fluid analysis. Differences in overall survival (OS) were assessed with standard statistical techniques.

Results: Patients who received a VPS and more than 3 IT chemotherapy sessions survived longer (n = 26; OS time from implantation 11.7 ± 3.6 months) than those who received an occludable shunt but no IT chemotherapy (n = 24; OS time from implantation 2.8 ± 0.7 months, P < .018). Peritoneal seeding appeared after shunt insertion in only two patients (3%).

Conclusions: This is the largest series reported to date of patients with LMD who had had shunts with on-off valves placed to relieve symptoms of intracranial hypertension. Use of IT chemotherapy and control of hydrocephalus via such shunts was associated with improved survival.

我们报告了我们使用带有开关阀和在线Ommaya储液器的脑室-腹膜分流器(VPS)治疗脑膜轻脑病(LMD)患者的脑积水或颅内高压的经验。我们的目的是确定控制颅内压升高联合鞘内化疗是否会延长患者的生存期。在这项经irb批准的回顾性研究中,我们回顾了1996年11月至2021年12月在安德森癌症中心接受带贮液器和开关阀的VPS治疗的58例实体癌成年LMD患者。原发肿瘤最常为黑色素瘤(n=19)或乳腺癌(n=20)。通过临床症状和磁共振成像(MRI)诊断脑积水,通过MRI或脑脊液分析诊断LMD。采用标准统计学技术评估总生存期(OS)的差异。接受VPS和超过3次IT化疗的患者存活时间更长(n=26;植入后的OS时间(11.7±3.6个月)比接受可闭塞分流术但未接受IT化疗的患者(n=24;种植后OS时间(2.8±0.7个月),p < 0.018。只有2例(3%)患者在插入分流器后出现腹膜播种。这是迄今为止报道的最大的一系列LMD患者,他们接受了带有开关阀的分流术来缓解颅内高压症状。使用IT化疗和通过此类分流控制脑积水可提高生存率。
{"title":"Ventriculoperitoneal shunting with an on-off valve for patients with leptomeningeal metastases and intracranial hypertension.","authors":"Kristin M Huntoon, Jaime Gasco, Isabella C Glitza Oliva, Sherise D Ferguson, Nazarin K Majd, Ian E McCutcheon","doi":"10.1093/nop/npad056","DOIUrl":"10.1093/nop/npad056","url":null,"abstract":"<p><strong>Background: </strong>We report our experience with using a ventriculoperitoneal shunt (VPS) with an on-off valve and in-line Ommaya reservoir for the treatment of hydrocephalus or intracranial hypertension in patients with leptomeningeal disease (LMD). Our goal was to determine whether control of intracranial pressure elevation combined with intrathecal (IT) chemotherapy would extend patient survival.</p><p><strong>Methods: </strong>In this IRB-approved retrospective study, we reviewed 58 cases of adult patients with LMD from solid cancers who received a VPS with a reservoir and an on-off valve at M D Anderson Cancer Center from November 1996 through December 2021. Primary tumors were most often melanoma (<i>n</i> = 19) or breast carcinoma (<i>n</i> = 20). Hydrocephalus was diagnosed by clinical symptoms and findings on magnetic resonance imaging (MRI), and LMD by MRI or cerebrospinal fluid analysis. Differences in overall survival (OS) were assessed with standard statistical techniques.</p><p><strong>Results: </strong>Patients who received a VPS and more than 3 IT chemotherapy sessions survived longer (<i>n</i> = 26; OS time from implantation 11.7 ± 3.6 months) than those who received an occludable shunt but no IT chemotherapy (<i>n</i> = 24; OS time from implantation 2.8 ± 0.7 months, <i>P</i> < .018). Peritoneal seeding appeared after shunt insertion in only two patients (3%).</p><p><strong>Conclusions: </strong>This is the largest series reported to date of patients with LMD who had had shunts with on-off valves placed to relieve symptoms of intracranial hypertension. Use of IT chemotherapy and control of hydrocephalus via such shunts was associated with improved survival.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10785578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47932935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health-related Quality of Life of Pediatric Brain Tumor Survivors after Treatment in Jordan 约旦儿童脑肿瘤幸存者治疗后的健康相关生活质量
Q2 Medicine Pub Date : 2023-08-31 DOI: 10.1093/nop/npad054
Han Choi, Amr S Soliman, Randa Al Mousa, Jennifer Yeh, Jamal Khader, Iyad Sultan, Ahmad K H Ibrahimi
Abstract Background The number of cancer survivors and survivorship are increasing. Health-related quality of life (HRQOL) has not been widely studied in low-and-middle-income countries (LMICs). The aim of this study is to explore HRQOL of childhood brain tumor survivors and its determinants in Jordan. Methods Health-related quality of life information was collected from 80 patients treated at the King Hussein Cancer Center and their parents using the Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales questionnaire in Arabic. Multivariable linear OLS regression models were used to analyze correlates of HRQOL and compare differences between child- and parent-reported responses. Results Health-related quality of life scores reported by survivors and by parents were positively correlated on all subscales and total PedsQL scores (r = 0.59, P = .001). Survivors reported better HRQOL in cognitive subscale (β = 0.56, P = .03) and worse HRQOL in work subscale (β = 0.43, P = .04), but no significant differences in the physical, emotional, and social subscales and total PedsQL scores. Significant predictors of HRQOL reported by parents and by children were different. Supratentorial tumor location was associated with a 10.97-unit lower physical HRQOL score, and recurrence of tumors predicted a 17.5-unit lower total HRQOL score, indicating worse quality of life. Male gender (β = 14.9, P = .002) and diagnosis of hypopituitarism (β = 16.1, P = .03) were associated with better HRQOL. Furthermore, patients that only had radiotherapy treatment had better emotional HRQOL (β = 32.9, P = .006) compared to patients that had combined radiotherapy and chemotherapy. Conclusion This study provides evidence on determinants of HRQOL of pediatric brain tumor patients in Jordan. Future studies need to capitalize on the findings of this study to institute a system for regular assessment of quality of life of pediatric cancer patients in Jordan and other countries with similar health care systems and sociocultural backgrounds.
摘要背景癌症幸存者的数量和生存率都在不断增加。与健康相关的生活质量(HRQOL)尚未在低收入和中等收入国家(LMICs)得到广泛研究。本研究的目的是探讨约旦儿童脑肿瘤幸存者的HRQOL及其决定因素。方法采用阿拉伯语儿科生活质量量表(PedsQL)通用核心量表,收集侯赛因国王癌症中心治疗的80例患者及其父母的健康相关生活质量信息。使用多变量线性OLS回归模型分析HRQOL的相关因素,并比较儿童和父母报告的反应之间的差异。结果幸存者和父母报告的健康相关生活质量评分在所有子量表和PedsQL总分上均呈正相关(r = 0.59, P = 0.001)。幸存者在认知亚量表中HRQOL较好(β = 0.56, P = 0.03),在工作亚量表中HRQOL较差(β = 0.43, P = 0.04),但在身体、情感和社会亚量表以及PedsQL总分上无显著差异。父母和孩子报告的HRQOL的显著预测因子存在差异。幕上肿瘤位置与物理HRQOL评分降低10.97个单位相关,肿瘤复发预测总HRQOL评分降低17.5个单位,表明生活质量较差。男性(β = 14.9, P = 0.002)和垂体功能减退(β = 16.1, P = 0.03)与较好的HRQOL相关。此外,单纯放疗患者的情绪HRQOL优于放化疗患者(β = 32.9, P = 0.006)。结论本研究为约旦儿童脑肿瘤患者HRQOL的影响因素提供了证据。未来的研究需要利用这项研究的结果,建立一个定期评估约旦和其他具有类似卫生保健系统和社会文化背景的国家儿童癌症患者生活质量的系统。
{"title":"Health-related Quality of Life of Pediatric Brain Tumor Survivors after Treatment in Jordan","authors":"Han Choi, Amr S Soliman, Randa Al Mousa, Jennifer Yeh, Jamal Khader, Iyad Sultan, Ahmad K H Ibrahimi","doi":"10.1093/nop/npad054","DOIUrl":"https://doi.org/10.1093/nop/npad054","url":null,"abstract":"Abstract Background The number of cancer survivors and survivorship are increasing. Health-related quality of life (HRQOL) has not been widely studied in low-and-middle-income countries (LMICs). The aim of this study is to explore HRQOL of childhood brain tumor survivors and its determinants in Jordan. Methods Health-related quality of life information was collected from 80 patients treated at the King Hussein Cancer Center and their parents using the Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales questionnaire in Arabic. Multivariable linear OLS regression models were used to analyze correlates of HRQOL and compare differences between child- and parent-reported responses. Results Health-related quality of life scores reported by survivors and by parents were positively correlated on all subscales and total PedsQL scores (r = 0.59, P = .001). Survivors reported better HRQOL in cognitive subscale (β = 0.56, P = .03) and worse HRQOL in work subscale (β = 0.43, P = .04), but no significant differences in the physical, emotional, and social subscales and total PedsQL scores. Significant predictors of HRQOL reported by parents and by children were different. Supratentorial tumor location was associated with a 10.97-unit lower physical HRQOL score, and recurrence of tumors predicted a 17.5-unit lower total HRQOL score, indicating worse quality of life. Male gender (β = 14.9, P = .002) and diagnosis of hypopituitarism (β = 16.1, P = .03) were associated with better HRQOL. Furthermore, patients that only had radiotherapy treatment had better emotional HRQOL (β = 32.9, P = .006) compared to patients that had combined radiotherapy and chemotherapy. Conclusion This study provides evidence on determinants of HRQOL of pediatric brain tumor patients in Jordan. Future studies need to capitalize on the findings of this study to institute a system for regular assessment of quality of life of pediatric cancer patients in Jordan and other countries with similar health care systems and sociocultural backgrounds.","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135830584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter regarding "Acceptability and feasibility of neurocognitive assessments with adults with primary brain cancer and brain metastasis: A systematic review". 关于“成人原发性脑癌和脑转移的神经认知评估的可接受性和可行性:一项系统综述”的信。
IF 2.4 Q2 CLINICAL NEUROLOGY Pub Date : 2023-08-30 eCollection Date: 2023-10-01 DOI: 10.1093/nop/npad043
M Gorter, J G Röttgering, V Belgers, P C De Witt Hamer, L Douw, M Klein
{"title":"Letter regarding \"Acceptability and feasibility of neurocognitive assessments with adults with primary brain cancer and brain metastasis: A systematic review\".","authors":"M Gorter, J G Röttgering, V Belgers, P C De Witt Hamer, L Douw, M Klein","doi":"10.1093/nop/npad043","DOIUrl":"10.1093/nop/npad043","url":null,"abstract":"","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10360907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Plasma exchange as a tool for removal of bevacizumab: Highlighting application for urgent surgery. 血浆置换作为去除贝伐单抗的工具:突出在紧急手术中的应用
IF 2.4 Q2 CLINICAL NEUROLOGY Pub Date : 2023-08-30 eCollection Date: 2023-12-01 DOI: 10.1093/nop/npad053
Bryan J Neth, Jeffrey L Winters, Revathi Thirumushi Sairaj, Ali Gharibi Loron, Masum Rahman, Renee Hirte, Cecile Riviere-Cazaux, Michael W Ruff, Terry C Burns

Background: Bevacizumab is commonly used to manage cerebral edema associated with brain tumors. However, its long half-life poses challenges for patients requiring urgent surgery due to wound complications. We present a case of utilizing therapeutic plasma exchange (TPE) to remove bevacizumab in a patient with recurrent glioblastoma requiring urgent surgery.

Methods: A 58-year-old male with recurrent glioblastoma, IDH-wildtype, presented with clinical and radiographic concern for ventriculitis requiring urgent wound washout only 4 days after his last bevacizumab infusion. TPE was performed for 3 sessions after surgery using a centrifugation-based cell separator. Replacement fluids included normal serum albumin, normal saline, and fresh frozen plasma. Bevacizumab levels were quantified using an enzyme-linked immunoabsorbent assay before and after each TPE session.

Results: TPE effectively removed bevacizumab, enabling safe surgery without new complications. Plasma bevacizumab levels decreased from 1087.63 to 145.35 ng/mL (13.4% of original) by the end of the last TPE session. This decline is consistent with nearly 3 half-lives, which compares favorably to the expected timeline of natural decline given the 21-day half-life.

Conclusions: We report a complex clinical scenario of a patient requiring urgent wound washout 4 days after last bevacizumab infusion for CNS infection. Surgery was successfully performed without new complications with use of TPE to remove bevacizumab immediately following surgery. This case highlights the feasibility of this approach, which may be utilized effectively in patients requiring surgery after having recently received bevacizumab.

贝伐单抗通常用于治疗脑肿瘤相关的脑水肿。然而,其较长的半衰期给因伤口并发症需要紧急手术的患者带来了挑战。我们提出了一个使用治疗性血浆交换(TPE)去除贝伐单抗的病例,患者复发性胶质母细胞瘤需要紧急手术。58岁男性复发性胶质母细胞瘤,idh -野生型,在最后一次贝伐单抗输注后仅4天,临床和影像学表现为脑室炎,需要紧急冲洗伤口。术后使用基于离心的细胞分离器进行3次TPE。替代液体包括正常血清白蛋白、生理盐水和新鲜冷冻血浆。在每次TPE之前和之后,使用酶联免疫吸收测定(ELISA)定量贝伐单抗水平。TPE有效去除贝伐单抗,使手术安全,无新的并发症。最后一次TPE治疗结束时,血浆贝伐单抗水平从1087.63 ng/mL降至145.35 ng/mL(为原始水平的13.4%)。这种下降与近三个半衰期相一致,这与考虑到21天半衰期的预期自然下降时间相比是有利的。我们报告了一个复杂的临床场景,患者在最后一次贝伐单抗输注后4天因中枢神经系统感染需要紧急伤口冲洗。手术成功进行,术后立即使用TPE去除贝伐单抗,无新的并发症。该病例强调了这种方法的可行性,它可以有效地用于最近接受贝伐单抗治疗后需要手术的患者。
{"title":"Plasma exchange as a tool for removal of bevacizumab: Highlighting application for urgent surgery.","authors":"Bryan J Neth, Jeffrey L Winters, Revathi Thirumushi Sairaj, Ali Gharibi Loron, Masum Rahman, Renee Hirte, Cecile Riviere-Cazaux, Michael W Ruff, Terry C Burns","doi":"10.1093/nop/npad053","DOIUrl":"10.1093/nop/npad053","url":null,"abstract":"<p><strong>Background: </strong>Bevacizumab is commonly used to manage cerebral edema associated with brain tumors. However, its long half-life poses challenges for patients requiring urgent surgery due to wound complications. We present a case of utilizing therapeutic plasma exchange (TPE) to remove bevacizumab in a patient with recurrent glioblastoma requiring urgent surgery.</p><p><strong>Methods: </strong>A 58-year-old male with recurrent glioblastoma, IDH-wildtype, presented with clinical and radiographic concern for ventriculitis requiring urgent wound washout only 4 days after his last bevacizumab infusion. TPE was performed for 3 sessions after surgery using a centrifugation-based cell separator. Replacement fluids included normal serum albumin, normal saline, and fresh frozen plasma. Bevacizumab levels were quantified using an enzyme-linked immunoabsorbent assay before and after each TPE session.</p><p><strong>Results: </strong>TPE effectively removed bevacizumab, enabling safe surgery without new complications. Plasma bevacizumab levels decreased from 1087.63 to 145.35 ng/mL (13.4% of original) by the end of the last TPE session. This decline is consistent with nearly 3 half-lives, which compares favorably to the expected timeline of natural decline given the 21-day half-life.</p><p><strong>Conclusions: </strong>We report a complex clinical scenario of a patient requiring urgent wound washout 4 days after last bevacizumab infusion for CNS infection. Surgery was successfully performed without new complications with use of TPE to remove bevacizumab immediately following surgery. This case highlights the feasibility of this approach, which may be utilized effectively in patients requiring surgery after having recently received bevacizumab.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666800/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47728978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploratory analysis of the spatial distribution of adult glioma age-adjusted county incidence rates, Nebraska Medicine, 2009-2019. 成人胶质瘤年龄调整县发病率空间分布的探索性分析,内布拉斯加州医学,2009-2019
IF 2.7 Q2 Medicine Pub Date : 2023-08-25 eCollection Date: 2024-02-01 DOI: 10.1093/nop/npad050
Kendra L Ratnapradipa, Amulya Yellala, Nicole Shonka

Background: Central nervous system (CNS) cancers including gliomas have low incidence but high mortality. The age-adjusted incidence rate for CNS cancers is higher in Nebraska than nationally. This exploratory study was motivated by glioma patient inquiries about possible clustering of cases within the state to see if more in-depth investigation was warranted.

Methods: Using electronic health records from Nebraska Medicine, we identified Nebraska adult (age ≥19) glioma patients diagnosed between January 1, 2009 and November 1, 2019. Patient residential addresses were geocoded, mapped, and combined with annual US Census data to compute age-adjusted incidence rates (AAIR) at the county level. Counties with fewer than five cases were excluded to protect patient identity. ArcGIS software was used for geocoding and mapping.

Results: Of the 285 cases included in the analysis, 53.2% were geocoded with exact match and the remainder were processed manually. Cases occurred in 47 of the 93 counties. After data suppression, 11 counties (228 cases) visually clustered in eastern and central Nebraska with AAIR ranging from 0.85 to 5.66 per 100 000.

Conclusions: Many counties in the state were excluded from analysis of this rare cancer due to the small number of cases leading to unstable rates and the need to suppress data to protect patient privacy. However, this preliminary study suggests that glioma incidence is highest in central and eastern Nebraska. Next steps include analysis of state cancer registry data to ensure more complete case ascertainment.

中枢神经系统(CNS)肿瘤包括神经胶质瘤发病率低但死亡率高。内布拉斯加州经年龄调整的中枢神经系统癌症发病率高于全国。这项探索性研究的动机是神经胶质瘤患者对该州可能聚集性病例的询问,以确定是否有必要进行更深入的调查。使用来自内布拉斯加州医学的电子健康记录,我们确定了2009年1月1日至2019年11月1日期间诊断的内布拉斯加州成人(年龄bb0 - 19岁)胶质瘤患者。对患者的居住地址进行地理编码、绘制地图,并结合美国年度人口普查数据计算县级年龄调整后的发病率(AAIR)。为保护患者身份,病例少于5例的县被排除在外。使用ArcGIS软件进行地理编码和制图。在纳入分析的285例病例中,53.2%的病例进行了精确匹配的地理编码,其余的病例进行了人工处理。93个县中有47个县发生了病例。数据压制后,11个县(228例)视觉聚集在内布拉斯加州东部和中部,AAIR范围为0.85 ~ 5.66 / 10万。该州的许多县都被排除在这种罕见癌症的分析之外,因为病例数量少,导致发病率不稳定,而且需要抑制数据以保护患者隐私。然而,这项初步研究表明,胶质瘤发病率最高的是内布拉斯加州中部和东部。接下来的步骤包括分析州癌症登记数据,以确保更完整的病例确定。
{"title":"Exploratory analysis of the spatial distribution of adult glioma age-adjusted county incidence rates, Nebraska Medicine, 2009-2019.","authors":"Kendra L Ratnapradipa, Amulya Yellala, Nicole Shonka","doi":"10.1093/nop/npad050","DOIUrl":"10.1093/nop/npad050","url":null,"abstract":"<p><strong>Background: </strong>Central nervous system (CNS) cancers including gliomas have low incidence but high mortality. The age-adjusted incidence rate for CNS cancers is higher in Nebraska than nationally. This exploratory study was motivated by glioma patient inquiries about possible clustering of cases within the state to see if more in-depth investigation was warranted.</p><p><strong>Methods: </strong>Using electronic health records from Nebraska Medicine, we identified Nebraska adult (age ≥19) glioma patients diagnosed between January 1, 2009 and November 1, 2019. Patient residential addresses were geocoded, mapped, and combined with annual US Census data to compute age-adjusted incidence rates (AAIR) at the county level. Counties with fewer than five cases were excluded to protect patient identity. ArcGIS software was used for geocoding and mapping.</p><p><strong>Results: </strong>Of the 285 cases included in the analysis, 53.2% were geocoded with exact match and the remainder were processed manually. Cases occurred in 47 of the 93 counties. After data suppression, 11 counties (228 cases) visually clustered in eastern and central Nebraska with AAIR ranging from 0.85 to 5.66 per 100 000.</p><p><strong>Conclusions: </strong>Many counties in the state were excluded from analysis of this rare cancer due to the small number of cases leading to unstable rates and the need to suppress data to protect patient privacy. However, this preliminary study suggests that glioma incidence is highest in central and eastern Nebraska. Next steps include analysis of state cancer registry data to ensure more complete case ascertainment.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10785590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48835344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to letter regarding “Assessing the association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas: A deeper look into potential confounding variables.” 对“评估高级别胶质瘤术前神经认知状态和IDH1突变状态之间的关系:对潜在混杂变量的深入研究”的回复。
Q2 Medicine Pub Date : 2023-08-25 DOI: 10.1093/nop/npad045
Evangelia Liouta, Aristotelis V Kalyvas, Spyridon Komaitis, Evangelos Drosos, Christos Koutsarnakis, Juan M García-Gómez, Javier Juan-Albarracín, Vasileios Katsaros, Theodosis Kalamatianos, Theodoros Argyrakos, George Stranjalis
Journal Article Response to letter regarding “Assessing the association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas: A deeper look into potential confounding variables.” Get access Evangelia Liouta, Evangelia Liouta Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceAthens Microneurosurgery LaboratoryHellenic Center for Neurosurgical Research “Prof. Petros Kokkalis”, Athens, Greece Corresponding Author: Evangelia Liouta, PhD, Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, Greece, Hellenic Center for Neurosurgical Research “Prof. Petros Kokkalis,” Athens, Greece (evangelialiouta286@hotmail.com). https://orcid.org/0000-0003-2948-9631 Search for other works by this author on: Oxford Academic Google Scholar Aristotelis V Kalyvas, Aristotelis V Kalyvas Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceDivision of Neurosurgery, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, ON, Canada https://orcid.org/0000-0002-0222-488X Search for other works by this author on: Oxford Academic Google Scholar Spyridon Komaitis, Spyridon Komaitis Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceAthens Microneurosurgery Laboratory https://orcid.org/0000-0002-7250-414X Search for other works by this author on: Oxford Academic Google Scholar Evangelos Drosos, Evangelos Drosos Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceAthens Microneurosurgery Laboratory https://orcid.org/0000-0002-0456-7317 Search for other works by this author on: Oxford Academic Google Scholar Christos Koutsarnakis, Christos Koutsarnakis Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceAthens Microneurosurgery Laboratory https://orcid.org/0000-0002-1363-5385 Search for other works by this author on: Oxford Academic Google Scholar Juan M García-Gómez, Juan M García-Gómez Grupo de Informática Biomédica (IBIME), Instituto de Aplicaciones de las Tecnologías de la Información y de las Comunicaciones Avanzadas (ITACA), Universitat Politècnica de València, Valencia, Spain Search for other works by this author on: Oxford Academic Google Scholar Javier Juan-Albarracín, Javier Juan-Albarracín Grupo de Informática Biomédica (IBIME), Instituto de Aplicaciones de las Tecnologías de la Información y de las Comunicaciones Avanzadas (ITACA), Universitat Politècnica de València, Valencia, Spain Search for other works by this author on: Oxford Academic Google Scholar Vasileios Katsaros, Vasileios Katsaros Department of Radiology, General Anti-Cancer and Oncological Hospital of Athens “St. Savvas,” Athens, Greece https://orcid.org/0000-0003-3087-1475 Search for ot
期刊文章对“评估高级别胶质瘤术前神经认知状态和IDH1突变状态之间的关系:对潜在混杂变量的深入研究”信函的回应。访问Evangelia Liouta, Evangelia Liouta神经外科,雅典国立和卡波distrian大学,Evangelismos医院,希腊雅典雅典微神经外科实验室,希腊神经外科研究中心“Prof. Petros Kokkalis”,希腊雅典Evangelia Liouta,博士,神经外科,雅典国立和Kapodistrian大学,Evangelismos医院,希腊雅典,希腊神经外科研究中心Petros Kokkalis教授,希腊雅典(evangelialiouta286@hotmail.com)。https://orcid.org/0000-0003-2948-9631搜索作者的其他作品:牛津学术谷歌学者Aristotelis V Kalyvas, Aristotelis V Kalyvas神经外科,雅典国立和卡波迪斯大学,希腊雅典Evangelismos医院神经外科,多伦多西部医院,大学健康网络,多伦多大学,多伦多,on,加拿大https://orcid.org/0000-0002-0222-488X搜索作者的其他作品:牛津学术谷歌学者Spyridon Komaitis, Spyridon Komaitis神经外科,雅典国立和Kapodistrian大学,Evangelismos医院,雅典微神经外科实验室https://orcid.org/0000-0002-7250-414X搜索作者的其他作品:牛津学术谷歌学者Evangelos Drosos, Evangelos Drosos神经外科,雅典国立和卡波迪兰大学,Evangelismos医院,雅典,希腊雅典微神经外科实验室https://orcid.org/0000-0002-0456-7317搜索作者的其他作品:牛津学术谷歌学者Christos Koutsarnakis, Christos Koutsarnakis神经外科,雅典国立和卡波迪斯特大学,Evangelismos医院,希腊雅典微神经外科实验室https://orcid.org/0000-0002-1363-5385牛津大学学术谷歌学者Juan M García-Gómez, Juan M García-Gómez西班牙巴伦西亚瓦伦西亚政治大学(Universitat politicnica de val ncia), las应用研究所Tecnologías de la Información y de las communicaciones Avanzadas (ITACA), Informática biomdica (IBIME)牛津大学学术谷歌学者Javier Juan-Albarracín, Javier Juan-Albarracín西班牙巴伦西亚瓦伦西亚政治大学应用研究所Tecnologías de la Información y de las communicaciones Avanzadas (ITACA) Informática biomacimica (IBIME)牛津学术谷歌学者Vasileios Katsaros, Vasileios Katsaros放射科,雅典“圣萨瓦斯”抗癌和肿瘤医院,希腊雅典https://orcid.org/0000-0003-3087-1475搜索作者的其他作品:牛津学术谷歌学者Theodosis Kalamatianos, Theodosis Kalamatianos神经外科,雅典国立和卡波迪斯特兰大学,Evangelismos医院,雅典,希腊雅典希腊神经外科研究中心“Prof. Petros Kokkalis”,希腊雅典https://orcid.org/0000-0003-4634-2965牛津学术谷歌学者Theodoros Argyrakos, Theodoros Argyrakos病理学部,福音医院,雅典,希腊搜索作者的其他作品:牛津学术谷歌学者…显示更多乔治·斯特兰加里斯乔治·斯特兰加里斯神经外科,雅典国立和卡波迪兰大学,Evangelismos医院,希腊雅典雅典微神经外科实验室,希腊神经外科研究中心“教授Petros Kokkalis”,希腊雅典https://orcid.org/0000-0002-9556-0101搜索作者的其他作品:牛津学术谷歌学者神经肿瘤学实践,npad045, https://doi.org/10.1093/nop/npad045出版:2023年8月25日
{"title":"Response to letter regarding “Assessing the association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas: A deeper look into potential confounding variables.”","authors":"Evangelia Liouta, Aristotelis V Kalyvas, Spyridon Komaitis, Evangelos Drosos, Christos Koutsarnakis, Juan M García-Gómez, Javier Juan-Albarracín, Vasileios Katsaros, Theodosis Kalamatianos, Theodoros Argyrakos, George Stranjalis","doi":"10.1093/nop/npad045","DOIUrl":"https://doi.org/10.1093/nop/npad045","url":null,"abstract":"Journal Article Response to letter regarding “Assessing the association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas: A deeper look into potential confounding variables.” Get access Evangelia Liouta, Evangelia Liouta Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceAthens Microneurosurgery LaboratoryHellenic Center for Neurosurgical Research “Prof. Petros Kokkalis”, Athens, Greece Corresponding Author: Evangelia Liouta, PhD, Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, Greece, Hellenic Center for Neurosurgical Research “Prof. Petros Kokkalis,” Athens, Greece (evangelialiouta286@hotmail.com). https://orcid.org/0000-0003-2948-9631 Search for other works by this author on: Oxford Academic Google Scholar Aristotelis V Kalyvas, Aristotelis V Kalyvas Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceDivision of Neurosurgery, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, ON, Canada https://orcid.org/0000-0002-0222-488X Search for other works by this author on: Oxford Academic Google Scholar Spyridon Komaitis, Spyridon Komaitis Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceAthens Microneurosurgery Laboratory https://orcid.org/0000-0002-7250-414X Search for other works by this author on: Oxford Academic Google Scholar Evangelos Drosos, Evangelos Drosos Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceAthens Microneurosurgery Laboratory https://orcid.org/0000-0002-0456-7317 Search for other works by this author on: Oxford Academic Google Scholar Christos Koutsarnakis, Christos Koutsarnakis Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceAthens Microneurosurgery Laboratory https://orcid.org/0000-0002-1363-5385 Search for other works by this author on: Oxford Academic Google Scholar Juan M García-Gómez, Juan M García-Gómez Grupo de Informática Biomédica (IBIME), Instituto de Aplicaciones de las Tecnologías de la Información y de las Comunicaciones Avanzadas (ITACA), Universitat Politècnica de València, Valencia, Spain Search for other works by this author on: Oxford Academic Google Scholar Javier Juan-Albarracín, Javier Juan-Albarracín Grupo de Informática Biomédica (IBIME), Instituto de Aplicaciones de las Tecnologías de la Información y de las Comunicaciones Avanzadas (ITACA), Universitat Politècnica de València, Valencia, Spain Search for other works by this author on: Oxford Academic Google Scholar Vasileios Katsaros, Vasileios Katsaros Department of Radiology, General Anti-Cancer and Oncological Hospital of Athens “St. Savvas,” Athens, Greece https://orcid.org/0000-0003-3087-1475 Search for ot","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135285641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing the association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas: A deeper look into potential confounding variables. 评估高级别胶质瘤术前神经认知状态和IDH1突变状态之间的关系:对潜在混杂变量的深入研究
IF 2.4 Q2 CLINICAL NEUROLOGY Pub Date : 2023-08-23 eCollection Date: 2023-12-01 DOI: 10.1093/nop/npad046
Aimen Waqar Khan, Syed Muhammad Mehdi Rizvi, Abdul Basit Khan, Maraj Ud Din, Zain Ul Abidin
{"title":"Assessing the association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas: A deeper look into potential confounding variables.","authors":"Aimen Waqar Khan, Syed Muhammad Mehdi Rizvi, Abdul Basit Khan, Maraj Ud Din, Zain Ul Abidin","doi":"10.1093/nop/npad046","DOIUrl":"10.1093/nop/npad046","url":null,"abstract":"","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44915262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multiscale network neuroscience in neuro-oncology: How tumors, brain networks, and behavior connect across scales. 神经肿瘤学中的多尺度网络神经科学:肿瘤、大脑网络和行为如何跨尺度连接
IF 2.4 Q2 CLINICAL NEUROLOGY Pub Date : 2023-08-22 eCollection Date: 2023-12-01 DOI: 10.1093/nop/npad044
Dorien A Maas, Linda Douw

Network neuroscience refers to the investigation of brain networks across different spatial and temporal scales, and has become a leading framework to understand the biology and functioning of the brain. In neuro-oncology, the study of brain networks has revealed many insights into the structure and function of cells, circuits, and the entire brain, and their association with both functional status (e.g., cognition) and survival. This review connects network findings from different scales of investigation, with the combined aim of informing neuro-oncological healthcare professionals on this exciting new field and also delineating the promising avenues for future translational and clinical research that may allow for application of network methods in neuro-oncological care.

网络神经科学是指对不同空间和时间尺度的大脑网络进行研究,并已成为理解大脑生物学和功能的主要框架。在神经肿瘤学中,对大脑网络的研究揭示了对细胞、电路和整个大脑的结构和功能的许多见解,以及它们与功能状态(如认知)和生存的关系。这篇综述将不同调查规模的网络发现联系起来,共同目的是让神经肿瘤学医疗保健专业人员了解这一令人兴奋的新领域,并为未来的转化和临床研究指明有希望的途径,从而将网络方法应用于神经肿瘤学护理。
{"title":"Multiscale network neuroscience in neuro-oncology: How tumors, brain networks, and behavior connect across scales.","authors":"Dorien A Maas, Linda Douw","doi":"10.1093/nop/npad044","DOIUrl":"10.1093/nop/npad044","url":null,"abstract":"<p><p>Network neuroscience refers to the investigation of brain networks across different spatial and temporal scales, and has become a leading framework to understand the biology and functioning of the brain. In neuro-oncology, the study of brain networks has revealed many insights into the structure and function of cells, circuits, and the entire brain, and their association with both functional status (e.g., cognition) and survival. This review connects network findings from different scales of investigation, with the combined aim of informing neuro-oncological healthcare professionals on this exciting new field and also delineating the promising avenues for future translational and clinical research that may allow for application of network methods in neuro-oncological care.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41250474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Neuro-oncology practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1